CA2784005C - Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) - Google Patents

Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) Download PDF

Info

Publication number
CA2784005C
CA2784005C CA2784005A CA2784005A CA2784005C CA 2784005 C CA2784005 C CA 2784005C CA 2784005 A CA2784005 A CA 2784005A CA 2784005 A CA2784005 A CA 2784005A CA 2784005 C CA2784005 C CA 2784005C
Authority
CA
Canada
Prior art keywords
photosensitizer
plga
nanoparticle
pharmaceutical formulation
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2784005A
Other languages
English (en)
French (fr)
Other versions
CA2784005A1 (en
Inventor
Klaus Langer
Thomas Knobloch
Beate Roder
Annegret Preuss
Volker Albrecht
Susanna Grafe
Arno Wiehe
Hagen Von Briesen
Karin Low
Sylvia Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec AG
Original Assignee
Biolitec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolitec AG filed Critical Biolitec AG
Publication of CA2784005A1 publication Critical patent/CA2784005A1/en
Application granted granted Critical
Publication of CA2784005C publication Critical patent/CA2784005C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2784005A 2009-12-11 2010-12-08 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) Expired - Fee Related CA2784005C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28589509P 2009-12-11 2009-12-11
US61/285,895 2009-12-11
US12/941,447 US20110275686A1 (en) 2009-12-11 2010-11-08 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)
US12/941,447 2010-11-08
PCT/US2010/059367 WO2011071970A2 (en) 2009-12-11 2010-12-08 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)

Publications (2)

Publication Number Publication Date
CA2784005A1 CA2784005A1 (en) 2011-06-16
CA2784005C true CA2784005C (en) 2018-01-02

Family

ID=44146154

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2784005A Expired - Fee Related CA2784005C (en) 2009-12-11 2010-12-08 Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)

Country Status (7)

Country Link
US (1) US20110275686A1 (enExample)
EP (1) EP2509633B1 (enExample)
JP (1) JP5868869B2 (enExample)
CN (2) CN102740892A (enExample)
BR (1) BR112012013951A2 (enExample)
CA (1) CA2784005C (enExample)
WO (1) WO2011071970A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211283B2 (en) * 2009-12-11 2015-12-15 Biolitec Pharma Marketing Ltd Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
GB0922066D0 (en) 2009-12-17 2010-02-03 Univ Belfast Modulator
WO2013012628A2 (en) * 2011-07-15 2013-01-24 The University Of Georgia Research Foundation, Inc. Immune-stimulating photoactive hybrid nanoparticles
JP2013094135A (ja) * 2011-11-02 2013-05-20 Waseda Univ 人工ナノ材料の安全性を評価する方法
CN103169968B (zh) * 2013-03-12 2014-11-26 中国科学院理化技术研究所 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用
US10188601B2 (en) * 2013-09-22 2019-01-29 Brenda Laster Continuous long-term controlled release of telomerase inhibitors
CN103933568B (zh) * 2014-05-12 2016-03-30 南京师范大学 一种水溶性竹红菌素plga纳米粒及其制备方法
EP3201201B1 (en) 2014-09-30 2022-01-26 biolitec unternehmensbeteiligungs II AG Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
WO2017019792A1 (en) * 2015-07-27 2017-02-02 The Texas A&M University System Surface active nanosystems
CN105343878B (zh) * 2015-11-30 2018-10-19 中国人民解放军第三军医大学第三附属医院 还原敏感型水溶性分子靶向光敏剂及其制备方法和应用
ES3011714T3 (en) 2016-02-26 2025-04-08 Biolitec Holding Gmbh & Co Kg Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
CN109481418B (zh) * 2017-12-19 2022-08-19 深圳先进技术研究院 抗肿瘤纳米颗粒及其制备方法和应用
EP3626268A1 (en) 2018-09-24 2020-03-25 Westfälische Wilhelms-Universität Münster Polymer-particle light-cleavable carrier systems for photodynamic therapy
US20220025185A1 (en) 2018-12-10 2022-01-27 Universitat Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
WO2020185658A1 (en) * 2019-03-08 2020-09-17 North Carolina State University Photothermal therapy promotes tumor infiltration and antitumor activity of cart t cells
CN111000804B (zh) * 2019-12-05 2022-02-11 东南大学 一种甘露糖靶向的热响应铂纳米颗粒及其制备方法和应用
CA3213957A1 (en) * 2021-04-07 2022-10-13 Jonathan S. Lindsey Porphyrin-hydroporphyrin compounds, compositions comprising the same and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3372558B2 (ja) * 1990-09-14 2003-02-04 中外製薬株式会社 マイクロカプセル型徐放性製剤及びその製造法
WO1997010811A1 (en) 1995-09-21 1997-03-27 Novartis Ag Nanoparticles in photodynamic therapy
JP3765338B2 (ja) * 1995-12-15 2006-04-12 武田薬品工業株式会社 注射用徐放性製剤の製造法
US5829448A (en) * 1996-10-30 1998-11-03 Photogen, Inc. Method for improved selectivity in photo-activation of molecular agents
GB0001455D0 (en) * 2000-01-21 2000-03-15 Scotia Holdings Plc Porphyrins and related compounds
WO2003092585A2 (en) * 2002-05-02 2003-11-13 Pr Pharmaceuticals, Inc. Controlled release compositions of estradiol metabolites
US7455858B2 (en) 2002-05-16 2008-11-25 Qlt Inc. Compositions and methods for delivery of photosensitive drugs
WO2004064751A2 (en) 2003-01-16 2004-08-05 St. Johns University New York Nanoparticle based stabilization of ir fluorescent dyes
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
US20090304803A1 (en) * 2005-06-06 2009-12-10 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy

Also Published As

Publication number Publication date
JP2013513610A (ja) 2013-04-22
US20110275686A1 (en) 2011-11-10
BR112012013951A2 (pt) 2018-06-05
EP2509633A2 (en) 2012-10-17
JP5868869B2 (ja) 2016-02-24
EP2509633C0 (en) 2025-06-18
CA2784005A1 (en) 2011-06-16
CN102740892A (zh) 2012-10-17
CN106913533A (zh) 2017-07-04
WO2011071970A3 (en) 2011-11-17
EP2509633B1 (en) 2025-06-18
WO2011071970A2 (en) 2011-06-16
EP2509633A4 (en) 2015-08-26

Similar Documents

Publication Publication Date Title
CA2784005C (en) Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)
Camerin et al. The in vivo efficacy of phthalocyanine–nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma
Palanikumar et al. pH-responsive upconversion mesoporous silica nanospheres for combined multimodal diagnostic imaging and targeted photodynamic and photothermal cancer therapy
Sarcan et al. Theranostic polymeric nanoparticles for NIR imaging and photodynamic therapy
Sztandera et al. Nanocarriers in photodynamic therapy—in vitro and in vivo studies
Mesquita et al. An insight on the role of photosensitizer nanocarriers for Photodynamic Therapy
Wang et al. Multifunctional biodegradable polyacrylamide nanocarriers for cancer theranostics A “see and treat” strategy
CA2784001C (en) Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
Bayir et al. Mesoporous silica nanoparticles in recent photodynamic therapy applications
Conte et al. Biodegradable core-shell nanoassemblies for the delivery of docetaxel and Zn (II)-phthalocyanine inspired by combination therapy for cancer
Teng et al. Phospholipid-functionalized mesoporous silica nanocarriers for selective photodynamic therapy of cancer
Bazylińska et al. Nanoemulsion-templated multilayer nanocapsules for cyanine-type photosensitizer delivery to human breast carcinoma cells
Chouikrat et al. Non polymeric nanoparticles for photodynamic therapy applications: recent developments
Lee et al. Polymeric nanoparticles for photodynamic therapy
Bœuf-Muraille et al. Evaluation of mTHPC-loaded PLGA nanoparticles for in vitro photodynamic therapy on C6 glioma cell line
Hao et al. Biomineralized Gd2O3@ HSA Nanoparticles as a Versatile Platform for Dual‐Modal Imaging and Chemo‐Phototherapy‐Synergized Tumor Ablation
Brezániová et al. Silica-based nanoparticles are efficient delivery systems for temoporfin
Geng et al. NIR-triggered ligand-presenting nanocarriers for enhancing synergistic photothermal-chemotherapy
Leandro et al. Evaluation of theranostic nanocarriers for near-infrared imaging and photodynamic therapy on human prostate cancer cells
Sun et al. Responsive peptide nanofibers with theranostic and prognostic capacity
Park et al. Development of DH-I-180-3 loaded lipid nanoparticle for photodynamic therapy
Gualdesi et al. Synthesis and physicochemical properties of polyacrylamide nanoparticles as photosensitizer carriers
Yu et al. GPX4 inhibition synergistically boosts mitochondria targeting nanoartemisinin-induced apoptosis/ferroptosis combination cancer therapy
Shapoval et al. Temoporfin-Conjugated PEGylated Poly (N, N-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic Therapy of Pancreatic Cancer
Efimova et al. Stimuli-responsive drug delivery systems based on bilayer lipid vesicles: new trends

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151203

MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191209